LA Cell is Sorrento’s partnership with City of Hope to focus on the development of groundbreaking cell-internalizing antibody therapies. The newly formed company combines City of Hope’s cell-internalizing technology with Sorrento’s fully human antibody library and immunotherapy expertise to enable the development of effective antibody therapies against crucial, yet elusive, intracellular targets.
LA Cell has exclusively licensed technology developed at City of Hope that enables modified monoclonal antibodies (mAbs) to penetrate into cells and target previously “undruggable” disease-causing proteins. The technology is based on a proprietary chemical modification of mAbs that allows the modified mAbs penetrating into cells while maintaining their ability to bind specific target proteins. This novel cell-internalizing technology of mAbs could be transformative for the field of biomedical research and biopharmaceutical development.
The ability to harness the inherent target specificity of antibodies against disease-causing molecules inside the cell could lead to the next generation of therapies against many severe diseases. Utilizing mAbs derived from Sorrento’s antibody portfolio, LA Cell is positioned to develop therapies against important oncology targets. The technology can also be applied to medically-relevant targets in other indications, such as inflammation, auto-immune disorders, diabetes, central nervous systems (CNS), cardiovascular diseases, and viral infections.